BEIJING, Nov. 30, 2015 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq:KANG), the largest provider in China’s fast growing private preventive healthcare services market with a market share of 13.6% in terms of revenue in calendar year 2014, today announced its unaudited financial results for the fiscal second quarter ended September 30, 2015.
Fiscal Second Quarter ended September 30, 2015 Financial Highlights
- Net revenues were US$98.6 million, an increase of 23.9% year-over-year
- Gross profit was US$45.5 million, an increase of 8.6% year-over-year
- Operating income was US$16.0 million, a decline of 24.1% year-over-year
- Non-GAAP operating income(1) was US$16.5 million, a decline of 24.2% year-over-year
- Non-GAAP EBITDA was US$24.1 million, a decline of 9.8% year-over-year
- Net income attributable to the Company was US$11.6 million, a decline of 24.9% year-over-year
- Non-GAAP net income attributable to the Company(2) was US$12.1 million, a decline of 24.9% year-over-year
- Basic and diluted income per ADS attributable to common shareholders were US$0.17 and US$0.17, respectively, as compared to US$0.24 and US$0.23, respectively, in the fiscal second quarter of 2014
- Non-GAAP basic and diluted income per ADS(3) attributable to common shareholders were US$0.18 and US$0.17, respectively, as compared to US$0.25 and US$0.24, respectively, in the fiscal second quarter of 2014
Fiscal Six Months ended September 30, 2015 Financial Highlights
- Net revenues were US$184.9 million, an increase of 32.3% year-over-year
- Gross profit was US$87.6 million, an increase of 23.5% year-over-year
- Operating income was US$30.4 million, an increase of 13.8% year-over-year
- Non-GAAP operating income(1) was US$31.4 million, a decline of 8.6% year-over-year
- Non-GAAP EBITDA was US$45.8 million, an increase of 6.5% year-over-year
- Net income attributable to the Company was US$22.3 million, an increase of 27.8% year-over-year
- Non-GAAP net income attributable to the Company(2) was US$23.3 million, a decline of 7.2% year-over-year
- Basic and diluted income per ADS attributable to common shareholders were US$0.32 and US$0.32, respectively, as compared to US$0.27 and US$0.26, respectively, in the fiscal six months of 2014
- Non-GAAP basic and diluted income per ADS(3) attributable to common shareholders were US$0.34 and US$0.33, respectively, as compared to US$0.39 and US$0.37, respectively, in the fiscal six months of 2014
(1) Non-GAAP operating income is defined as income from operations excluding share-based compensation expenses. For more information on these non-GAAP financial measures, please see the section captioned under “Non-GAAP Financial Measures” and the tables captioned “Reconciliation of GAAP and Non-GAAP Results” set forth at the end of this release.
(2) Non-GAAP net income attributable to the Company is defined as net income attributable to the Company excluding share-based compensation expenses.
(3) Non-GAAP basic and diluted earnings per ADS is defined as non-GAAP net income divided by weighted average number of basic and diluted ADS.
Mr. Lee Ligang Zhang, Chairman and Chief Executive Officer of iKang, commented on the results. “I am pleased with our performance with an increase in total net revenue by 32.3% year-over-year for Fiscal six months ended September 30, 2015. The Company’s performance was fully in line with our expectations.
“We have made great strides in executing on our strategic objectives to expand into new areas of growth and strengthen our capabilities as the prime mover in China’s fast moving private preventive healthcare services market. iKang acquired three high quality former Ciming franchisees in August that serves to consolidate our nationwide network of medical centres, and we will continue to augment our coverage with strategic high-end, high quality centres. We have also continued our investment for the future of iKang by expediting our expansion in the mobile healthcare space.”
Mr. Zhang concluded, “At a time when our strategic initiatives are bearing fruit and new niche services are underway, our greater focus on the increased integration of our newly acquired centres will enable us to further enhance our business line. We remain unwavering in our commitment to focus on growing our network, executing on our transformation strategies and building our business for the long run.”
FISCAL SECOND QUARTER ENDED SEPTEMBER 30, 2015 UNAUDITED FINANCIAL RESULTS
Net Revenues
Net revenues for the fiscal second quarter were US$98.6 million, representing a 23.9% increase from US$79.6 million in the same period in the last fiscal year. On a constant dollar basis, the growth would be 26.7%. As of September 30, 2015, the number of self-owned medical centers totalled 77 compared to 50 as of September 30, 2014. In the quarter, the Company served approximately a total of 1,245,000 customer visits under both corporate and individual programs, representing an increase of 27.4% over the fiscal second quarter of 2014.
The table below sets forth a breakdown of net revenues:
| (US$ million) | 2nd Fiscal Quarter Ended September 30, 2015 | 2nd Fiscal Quarter Ended September 30, 2014 | YoY % Change | ||
| Medical Examinations | 83.6 | 68.3 | 22.4 | % | |
| Disease Screening | 7.0 | 5.3 | 33.5 | % | |
| Dental Services | 1.6 | 0.7 | 109.8 | % | |
| Other Services | 6.4 | 5.3 | 20.8 | % | |
| Total | 98.6 | 79.6 | 23.9 | % | |
Medical Examinations: Net revenues for the quarter were US$83.6 million, representing a 22.4% increase from US$68.3 million in the same period of last fiscal year.
Disease Screening: Net revenues for the quarter were US$7.0 million, representing a 33.5% increase from US$5.3 million in the same period of last fiscal year. Disease screening services refer to the additional services requested by individuals under the basic corporate medical examination programs as a result of individual needs.
Dental Services: Net revenues for the quarter were US$1.6 million, representing a 109.8% increase from US$0.7 million in the same period in the last fiscal year.
Other Services: Net revenues for the quarter were US$6.4 million, representing a 20.8% increase from US$5.3 million in the same period in the last fiscal year, which was mainly due to the incremental revenue contribution from outpatient services, medical consultancy services and packaged medical services.
Cost of Revenues
Cost of revenues for the quarter was US$53.2 million, representing a 40.9% increase from US$37.7 million in the same period in the last fiscal year.
Gross Profit and Gross Margin
Gross profit for the quarter was US$45.5 million, representing an 8.6% increase from US$41.9 million in the same period in the last fiscal year. Gross margin for the quarter was 46.1%, as compared to 52.6% in the second quarter of fiscal 2014. Gross margin was diluted mainly due to the additions of newly acquired medical centers which has lower gross margin as they were still in the ramping up period.
Operating Expenses
Total operating expenses for the quarter were US$29.5 million, representing a 41.6% increase from US$20.8 million in the same period in the last fiscal year.
Selling and marketing expenses
Selling and marketing expenses for the quarter were US$14.5 million, accounting for 14.7% of total net revenues as compared to 12.0% in the same period in the last fiscal year. The increase in the selling and marketing expenses was mainly due to the expansion of sales and marketing team and the increase in our investment in brand building to further upgrade our high-quality image.
General and administrative expenses
General and administrative expenses for the quarter were US$14.1 million, accounting for 14.3% of total net revenues as compared to 13.8% in the same period in the last fiscal year.
Research and development expenses
Research and development expenses for the quarter were US$961,000, accounting for 1.0% of total net revenues as compared to 0.4% in the same period in the last fiscal year.
Income from Operations
Income from operations for the quarter was US$16.0 million, representing a 24.1% decrease from US$21.1 million in the same period in the last fiscal year. Excluding share-based compensation of US$489,000 for this quarter and US$649,000 for the same quarter last year, non-GAAP income from operations for the quarter was US$16.5 million as compared to US$21.7 million, which reflected a decline of 24.2%.
Net Income
Net income attributable to the Company for the quarter was US$11.6 million, representing a decrease of 24.9% from US$15.5 million for the same period in the last fiscal year.
Non-GAAP net income for the quarter was US$12.1 million, representing a decline of 24.9% from US$16.1 million for the same period in fiscal 2014.
Basic and Diluted Earnings per ADS
Basic and diluted income per ADS attributable to common shareholders were US$0.17 and US$0.17, respectively, compared to basic and diluted income per ADS attributable to common shareholders of US$0.24 and US$0.23, respectively, in the same quarter of fiscal 2014.
Non-GAAP basic and diluted income per ADS attributable to common shareholders were US$0.18 and US$0.17, respectively, compared to basic and diluted income per ADS attributable to common shareholders of US$0.25 and US$0.24, respectively, in the same quarter of fiscal 2014.
FISCAL SIX MONTHS ENDED SEPTEMBER 30, 2015 UNAUDITED FINANCIAL RESULTS
Net Revenues
Net revenues for the fiscal six months were US$184.9 million, representing a 32.3% increase from US$139.8 million in the same period in the last fiscal year. On a constant dollar basis, the growth would be 33.7%. From the beginning of year, we have in total added 19 new medical centers, in which 18 were acquired. During this period, the Company served approximately a total of 2,281,000 customer visits under both corporate and individual programs, representing an increase of 29.1% over the fiscal six months of 2014.
The table below sets forth a breakdown of net revenues:
| (US$ million) | Fiscal Six Months Ended September 30, 2015 | Fiscal Six Months Ended September 30, 2014 | YoY % Change | ||
| Medical Examinations | 155.6 | 119.8 | 29.9 | % | |
| Disease Screening | 12.5 | 9.5 | 32.6 | % | |
| Dental Services | 3.1 | 1.3 | 132.5 | % | |
| Other Services | 13.7 | 9.2 | 48.8 | % | |
| Total | 184.9 | 139.8 | 32.3 | % | |
Medical Examinations: Net revenues for the period were US$155.6 million, representing a 29.9% increase from US$119.8 million in the same period of last fiscal year. The strong performance was primarily due to an increase of 31.5% in the number of customer visits for medical examinations during the period while the blended average selling price remained stable around RMB450.
Disease Screening: Net revenues for the period were US$12.5 million, representing a 32.6% increase from US$9.5 million in the same period of last fiscal year.
Dental Services: Net revenues for the period were US$3.1 million, representing a 132.5% increase from US$1.3 million in the same period in the last fiscal year.
Other Services: Net revenues for the period were US$13.7 million, representing a 48.8% increase from US$9.2 million in the same period in the last fiscal year.
Cost of Revenues
Cost of revenues for the period was US$97.3 million, representing a 41.4% increase from US$68.8 million in the same period in the last fiscal year.
Gross Profit and Gross Margin
Gross profit for the period was US$87.6 million, representing a 23.5% increase from US$71.0 million in the same period in the last fiscal year. Gross margin for the quarter was 47.4%, as compared to 50.8% in the same period of fiscal 2014. Gross margin was diluted mainly due to the additions of newly acquired medical centers which has lower gross margin as they were still in the ramping up period.
Operating Expenses
Total operating expenses for the period were US$57.2 million, representing a 29.3% increase from US$44.3 million in the same period in the last fiscal year.
Selling and marketing expenses
Selling and marketing expenses for the period were US$28.5 million, accounting for 15.4% of total net revenues as compared to 11.8% in the same period in the last fiscal year. The increase in the selling and marketing expenses was mainly due to the expansion of sales and marketing team and the increase in our investment in brand building to further upgrade our high-quality image.
General and administrative expenses
General and administrative expenses for the period were US$27.1 million, accounting for 14.6% of total net revenues as compared to 19.5% in the same period in the last fiscal year. Excluding share-based compensation of US$981,000 for this period and US$7,625,000 for the same period last year, non-GAAP general and administrative expenses for the period would be US$26.1 million as compared to US$19.6 million in the same period in the last fiscal year, which reflected an increase of 32.9%.
Research and development expenses
Research and development expenses for the period were US$1.7 million, accounting for 0.9% of total net revenues as compared to 0.4% in the same period in the last fiscal year.
Income from Operations
Income from operations for the period was US$30.4 million, representing a 13.8% increase from US$26.7 million in the same period in the last fiscal year. Excluding share-based compensation of US$981,000 for this period and US$7,625,000 for the same period last year, non-GAAP income from operations for the period was US31.4 million as compared to US$34.3 million, which reflected a decline of 8.6%.
Net Income
Net income attributable to the Company for the period was US$22.3 million, representing an increase of 27.8% from US$17.4 million for the same period in the last fiscal year.
Non-GAAP net income for the period was US$23.3 million, representing a decline of 7.2% from US$25.1 million for the same period in fiscal 2014.
Basic and Diluted Earnings per ADS
Basic and diluted income per ADS attributable to common shareholders were US$0.32 and US$0.32, respectively, compared to basic and diluted income per ADS attributable to common shareholders of US$0.27 and US$0.26, respectively, in the same period of fiscal 2014.
Non-GAAP basic and diluted income per ADS attributable to common shareholders were US$0.34 and US$0.33, respectively, compared to basic and diluted income per ADS attributable to common shareholders of US$0.39 and US$0.37, respectively, in the same period of fiscal 2014.
Cash and Working Capital
As of September 30, 2015, the Company’s cash and cash equivalents, restricted cash and term deposit totaled US$98.4 million, as compared to US$113.0 million as of June 30, 2015.
The net working capital was totaled US$74.9 million as of September 30, 2015, with current assets of totaled US$254.1 million and current liabilities of totaled US$179.1 million, compared to net working capital of US$76.4 million as of June 30, 2015.
Conference Call
iKang’s management will host a conference call at 8:00 am US Eastern Time (9:00 pm Beijing/Hong Kong Time) on December 1, 2015, to discuss its quarterly results and recent business activities.
To participate in the conference call, please dial the following number five to ten minutes prior to the scheduled conference call time:
China: 4001-200-539
Hong Kong: 800-905-927
United States: 1855-298-3404
International: +65-6823-2299
Passcode: 2883872
The Company will also broadcast a live audio webcast of the conference call. The webcast will be available at http://ir.ikang.com.
Following the earnings conference call, an archive of the call will be available by dialing:
China: 4001-842-240
Hong Kong: 800-966-697
United States: 1866-846-0868
International: +61-2-9641-7900
Replay Passcode: 2883872
Replay End Date: December 14, 2015
STATEMENT REGARDING UNAUDITED FINANCIAL INFORMATION
The unaudited financial information set forth above is subject to adjustments that may be identified when audit work is performed on the Company’s year-end financial statements, which could result in significant differences from this unaudited financial information.
NON-GAAP FINANCIAL MEASURES
To supplement our consolidated financial statements which are presented in accordance with U.S. GAAP, we also use non-GAAP operating income, non-GAAP net income and non-GAAP EBITDA as additional non-GAAP financial measures. We present these non-GAAP financial measures because they are used by our management to evaluate our operating performance. We also believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our consolidated results of operations in the same manner as our management and in comparing financial results across accounting periods and to those of our peer companies.
Reconciliation of non-GAAP operating income, non-GAAP net income and non-GAAP EBITDA to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP is set forth at the end of this release.
About iKang Healthcare Group, Inc.
iKang Healthcare Group, Inc. is the largest provider in China’s fast growing private preventive healthcare services market, accounting for approximately 13.6% of market share in terms of revenue in calendar year 2014.
Through iKang’s integrated service platform and established nationwide network of medical centers and third-party service provider facilities, the Company provides comprehensive and high quality preventive healthcare solutions, including a wide range of medical examinations services and value-added services including disease screening and other services. iKang’s customers are primarily corporate customers who contract the Company to provide medical examination services to their employees and clients, and pay for these services at pre-negotiated prices. iKang also directly markets its services to individual customers. In the fiscal year ended March 31, 2015, the Company served a total of 3.6 million customer visits under both corporate and individual programs. For the first six months ended September 30, 2015, the Company served a total of 2,281,000 customer visits.
As of November 30, 2015, iKang’s nationwide network consisted of 80 (1) self-owned medical centers covering 22 of the most affluent cities in China, namely Beijing, Shanghai, Guangzhou, Shenzhen, Chongqing, Tianjin, Nanjing, Suzhou, Hangzhou, Chengdu, Fuzhou, Changchun, Jiangyin, Changzhou, Wuhan, Changsha, Yantai, Yinchuan, Weihai, Weifang and Shenyang, as well as Hong Kong. The Company has also supplemented its self-owned medical center network by contracting with approximately 400 third-party service provider facilities in over 150 cities, which include selected independent medical examination centers and hospitals across all of China’s provinces, creating a nationwide network that allows iKang to serve its customers in markets where it does not have self-owned medical centers.
(1) Among the 80 self-owned medical centers, two medical centers are currently operated primarily by the minority shareholders of these medical centers or their parent company.
Forward-looking Statements
This press release contains forward-looking statements. These statements, including management quotes and business outlook, are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as ”will,” "estimate," "project," "predict," "believe," "expect," "anticipate," "intend," "potential," "plan," "goal" and similar statements. iKang may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the Company’s goals and strategies; its future business development, financial condition and results of operations; its ability to retain and grow its customer base and network of medical centers; the growth of, and trends in, the markets for its services in China; the demand for and market acceptance of its brand and services; competition in its industry in China; relevant government policies and regulations relating to the corporate structure, business and industry; fluctuations in general economic and business conditions in China. Further information regarding these and other risks is included in iKang’s filing with the Securities and Exchange Commission. iKang undertakes no duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
| IKANG HEALTHCARE GROUP, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (In thousands of US dollars, except share data and per share data, or otherwise noted) | ||||||||
| (Unaudited) | ||||||||
| As of | As of | |||||||
| March 31, | September 30, | |||||||
| 2015 | 2015 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 97,336 | $ | 60,774 | ||||
| Restricted cash | 54,417 | 32,299 | ||||||
| Term deposit | 14,621 | 5,289 | ||||||
| Accounts receivable, net of allowance for doubtful accounts of $8,055 | ||||||||
| and $9,806 as of March 31, 2015 and September 30, 2015, respectively | 59,650 | 99,946 | ||||||
| Inventories | 2,661 | 3,277 | ||||||
| Deferred tax assets-current | 5,949 | 5,643 | ||||||
| Prepaid expenses and other current assets | 44,031 | 46,858 | ||||||
| Total current assets | $ | 278,665 | $ | 254,086 | ||||
| Property and equipment, net | $ | 105,022 | $ | 123,840 | ||||
| Acquired intangible assets, net | 30,634 | 37,714 | ||||||
| Goodwill | 72,101 | 102,864 | ||||||
| Long-term investment | 129 | 20,550 | ||||||
| Deferred tax assets-non-current | 2,212 | 3,529 | ||||||
| Rental deposit and other non-current assets | 10,238 | 11,861 | ||||||
| TOTAL ASSETS | $ | 499,001 | $ | 554,444 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable (including accounts payable of the consolidated VIEs | ||||||||
| without recourse to iKang Healthcare Group, Inc. of $19,530 | ||||||||
| and $29,681 of March 31, 2015 and September 30, 2015, respectively) | $ | 23,526 | $ | 34,281 | ||||
| Accrued expenses and other current liabilities (including accrued expenses | ||||||||
| and other current liabilities of the consolidated VIEs without recourse | ||||||||
| to iKang Healthcare Group, Inc. of $30,631 and $30,909 of March 31, 2015 | ||||||||
| and September 30, 2015, respectively) | 36,790 | 36,286 | ||||||
| Income tax payable (including income tax payable of the consolidated VIEs | ||||||||
| without recourse to iKang Healthcare Group, Inc. of $6,254 and | ||||||||
| $7,443 of March 31, 2015 and September 30, 2015, respectively) | 7,539 | 10,994 | ||||||
| Deferred revenues (including deferred revenues of the consolidated VIEs | ||||||||
| without recourse to iKang Healthcare Group, Inc. of $31,786 and | ||||||||
| $47,313 of March 31, 2015 and September 30, 2015, respectively) | 38,457 | 52,849 | ||||||
| Deferred government subsidy-current (including deferred government | ||||||||
| subsidy-current of the consolidated VIEs without recourse to iKang | ||||||||
| Healthcare Group, Inc. of $63 and $15 of March 31, 2015 and | ||||||||
| September 30, 2015, respectively) | 63 | 15 | ||||||
| Short term borrowings (including short term borrowings of the consolidated | ||||||||
| VIEs without recourse to iKang Healthcare Group, Inc. of $56,772 | ||||||||
| and $44,699 of March 31, 2015 and September 30, 2015, respectively) | 56,772 | 44,699 | ||||||
| Total current liabilities | $ | 163,147 | $ | 179,124 | ||||
| IKANG HEALTHCARE GROUP, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS - continued | ||||||||
| (In thousands of US dollars, except share data and per share data, or otherwise noted) | ||||||||
| (Unaudited) | ||||||||
| As of | As of | |||||||
| March 31, | September 30, | |||||||
| 2015 | 2015 | |||||||
| Deferred tax liabilities-non-current (including deferred tax liabilities | ||||||||
| non-current of the consolidated VIEs without recourse to iKang | ||||||||
| Healthcare Group, Inc. of $6,670 and $9,533 of March 31, 2015 and | ||||||||
| September 30, 2015, respectively) | $ | 7,506 | $ | 9,896 | ||||
| TOTAL LIABILITIES | $ | 170,653 | $ | 189,020 | ||||
| Equity: | ||||||||
| Total iKang Healthcare Group, Inc. shareholders' equity | $ | 319,130 | $ | 349,083 | ||||
| Non-controlling interests | $ | 9,218 | $ | 16,341 | ||||
| TOTAL EQUITY | $ | 328,348 | $ | 365,424 | ||||
| TOTAL LIABILITIES AND EQUITY | $ | 499,001 | $ | 554,444 | ||||
| IKANG HEALTHCARE GROUP, INC. | |||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||
| (In thousands of US dollars, except share data and per share data, or otherwise noted) | |||||||||||||
| (Unaudited) | |||||||||||||
| Three- month periods | Six- month periods | ||||||||||||
| ended September 30 | ended September 30 | ||||||||||||
| 2014 | 2015 | 2014 | 2015 | ||||||||||
| Net revenues | $ | 79,627 | $ | 98,642 | $ | 139,791 | $ | 184,939 | |||||
| Cost of revenues | 37,722 | 53,152 | 68,817 | 97,304 | |||||||||
| Gross profit | $ | 41,905 | $ | 45,490 | $ | 70,974 | $ | 87,635 | |||||
| Operating expenses: | |||||||||||||
| Selling and marketing expenses | $ | 9,566 | $ | 14,453 | $ | 16,490 | $ | 28,484 | |||||
| General and administrative expenses | 10,983 | 14,101 | 27,254 | 27,068 | |||||||||
| Research and development expenses | 297 | 961 | 521 | 1,678 | |||||||||
| Total operating expenses | $ | 20,846 | $ | 29,515 | $ | 44,265 | $ | 57,230 | |||||
| Income from operations | $ | 21,059 | $ | 15,975 | $ | 26,709 | $ | 30,405 | |||||
| Loss from forward contracts | - | - | (8 | ) | - | ||||||||
| Interest expense | 859 | 393 | 1,313 | 789 | |||||||||
| Interest income | 283 | 108 | 348 | 294 | |||||||||
| Other income | 883 | - | 883 | - | |||||||||
| Income before income tax expenses and gain from | |||||||||||||
| equity method investment | $ | 21,366 | $ | 15,690 | $ | 26,619 | $ | 29,910 | |||||
| Income tax expenses | 5,679 | 4,174 | 9,328 | 7,957 | |||||||||
| Gain from equity method investment | - | - | 521 | - | |||||||||
| Net income | $ | 15,687 | $ | 11,516 | $ | 17,812 | $ | 21,953 | |||||
| Less: Net income/(loss) attributable to non-controlling interest | 200 | (107 | ) | 378 | (332 | ) | |||||||
| Net income attributable to iKang Healthcare Group, Inc. | $ | 15,487 | $ | 11,623 | $ | 17,434 | $ | 22,285 | |||||
| Deemed dividend to preferred shareholders | - | - | 100 | - | |||||||||
| Undistributed earnings allocated to preferred shareholders | - | - | 201 | - | |||||||||
| Net income attributable to common shareholders | |||||||||||||
| of iKang Healthcare Group, Inc. | $ | 15,487 | $ | 11,623 | $ | 17,133 | $ | 22,285 | |||||
| Net income per share attributable to common shareholders | |||||||||||||
| of iKang Healthcare Group, Inc. | |||||||||||||
| Basic | $ | 0.47 | $ | 0.34 | $ | 0.54 | $ | 0.65 | |||||
| Diluted | $ | 0.45 | $ | 0.33 | $ | 0.52 | $ | 0.63 | |||||
| Net income per ADS (one common share equals to two ADSs) | |||||||||||||
| Basic | $ | 0.24 | $ | 0.17 | $ | 0.27 | $ | 0.32 | |||||
| Diluted | $ | 0.23 | $ | 0.17 | $ | 0.26 | $ | 0.32 | |||||
| Weighted average shares used in calculating net income | |||||||||||||
| per common share | |||||||||||||
| Basic | 32,752,409 | 34,361,539 | 31,493,935 | 34,361,539 | |||||||||
| Diluted | 34,186,773 | 35,218,237 | 32,807,038 | 35,231,324 | |||||||||
| IKANG HEALTHCARE GROUP, INC. | |||||||||||||
| RECONCILIATION OF GAAP AND NON-GAAP RESULTS | |||||||||||||
| (In thousands of US dollars, except share data and per share data, or otherwise noted) | |||||||||||||
| (Unaudited) | |||||||||||||
| Three- month periods | Six- month periods | ||||||||||||
| ended September 30 | ended September 30 | ||||||||||||
| 2014 | 2015 | 2014 | 2015 | ||||||||||
| Income from operations | $ | 21,059 | $ | 15,975 | $ | 26,709 | $ | 30,405 | |||||
| Add: | |||||||||||||
| Share-based compensation expenses | 649 | 489 | 7,625 | 981 | |||||||||
| Non-GAAP operating income | $ | 21,708 | $ | 16,464 | $ | 34,334 | $ | 31,386 | |||||
| Net income attributable to iKang Healthcare Group, Inc. | $ | 15,487 | $ | 11,623 | $ | 17,434 | $ | 22,285 | |||||
| Add: | |||||||||||||
| Share-based compensation expenses | 649 | 489 | 7,625 | 981 | |||||||||
| Non-GAAP net income | $ | 16,136 | $ | 12,112 | $ | 25,059 | $ | 23,266 | |||||
| Income from operations | $ | 21,059 | $ | 15,975 | $ | 26,709 | $ | 30,405 | |||||
| Add: | |||||||||||||
| Depreciation and amortization | 4,976 | 7,618 | 8,654 | 14,394 | |||||||||
| Share-based compensation expenses | 649 | 489 | 7,625 | 981 | |||||||||
| Non-GAAP EBITDA | $ | 26,684 | $ | 24,082 | $ | 42,988 | $ | 45,780 | |||||
| Non-GAAP net income attributable to preferred shareholders | |||||||||||||
| of iKang Healthcare Group, Inc. | $ | - | $ | - | $ | 698 | $ | - | |||||
| Non-GAAP net income attributable to common shareholders | |||||||||||||
| of iKang Healthcare Group, Inc. | $ | 16,136 | $ | 12,112 | $ | 24,361 | $ | 23,266 | |||||
| Non-GAAP net income per share attributable to common shareholders | |||||||||||||
| of iKang Healthcare Group, Inc. | |||||||||||||
| Basic | $ | 0.49 | $ | 0.35 | $ | 0.77 | $ | 0.68 | |||||
| Diluted | $ | 0.47 | $ | 0.34 | $ | 0.74 | $ | 0.66 | |||||
| Non-GAAP net income per ADS (one common share equals to two ADSs) | |||||||||||||
| Basic | $ | 0.25 | $ | 0.18 | $ | 0.39 | $ | 0.34 | |||||
| Diluted | $ | 0.24 | $ | 0.17 | $ | 0.37 | $ | 0.33 | |||||